Malaysia Collaborates with Two Prominent Singapore Organisations to Advance Clinical Research (VIDEO)

L-R: Dr. Zubaidah Zakariah, Prof. Chng Wee Joo, Dr. Akhmal Yusof, Dato’ Dr. Fadzillah Kamaludin, Datuk Dr. Noor Hisham Abdullah, Datuk Seri Dr. Dzulkefly Ahmad, Mr. Choo Chee Kong, Dato’ Seri Dr. Chen Chaw Min, Dato’ Dr. Goh Pik Pin

KUALA LUMPUR, 26 February 2019 – Clinical Research Malaysia (CRM) inked two Memorandum of Understanding (MoU) with two prominent Singapore organizations in the field of clinical research. This will further pave the way for better Malaysia–Singapore collaborations in advancing drug development and research capabilities between both countries. Read more

CRM’s New Office Launched by Minister of Health, YB Datuk Seri Dr Dzulkefly Ahmad

CRM’s new office was launched by the Minister of Health Malaysia, YB Datuk Seri Dr Dzulkefly Ahmad on 26th February 2019. It was witnessed by members of CRM’s Board of Directors, CRM’s Senior Leadership Team and member of the press.

Our humble gratitude to the YB Minister for gracing us with his presence.

Making it Official! ISO 9001:2015

Making it official! We would like to thank you Mr. Zakaria Mohamad Nor, Head of Section (Management System Certification) from SIRIM QAS International​ to officially handing over the ISO 9001:2015 certificate to us at the CRM National Conference 2019 recently held at Menara SuezCap, KL.

We are ISO 9001:2015 certified!

We are delighted to announce that Clinical Research Malaysia is now ISO 9001:2015 certified!

ISO 9001 is the most widely used and recognised standard for Quality Management System internationally. To become ISO 9001:2015 certified, Clinical Research Malaysia has met the requirements set out in and have been audited by SIRIM QAS International Sdn Bhd in accordance with the 9001 standard.

It is an achievement that shows our commitment to become a global trusted company.

 

PhAMA Industry Fact Book: 2018 Edition

Clinical Research Malaysia has contributed our insights for Industry Sponsored Research (ISR) in the Pharmaceutical Association of Malaysia (PhAMA) Industry Fact Book: 2018 Edition (pg. 74 – 80) which was launched by Health Minister Datuk Seri Dr Dzulkefly Ahmad on 8 January 2018.

Download the latest PhAMA Industry Fact Book: 2018 Edition today!

 


 

 

 

Director-General of Health, Malaysia Visit to CRM New Office

We received a visit by YBhg. Datuk Dr. Noor Hisham Abdullah, Director General of Health, Ministry of Health, Malaysia earlier this morning to our new office located at Menara SuezCap, KL. Thank you Datuk, for your the great support in clinical research and visiting us!

Malaysia Pharma Report 2018

Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Tun Dr. Mahathir Mohamad spearheading a bold health policy reform.

Also explored is the emergence of the halal medicine niche – where Malaysia has the potential to be a global leader given its geographic links to Southeast Asia and cultural ties to the Middle East – the first Malaysian biosimilars, the country’s outstanding potential as a regional clinical research hub and the rise of medical tourism.

Malaysian breakthrough in clinical study on ovarian cancer blood test – BERNAMA

Dr. Akhmal Yusof, CEO of Clinical Research Malaysia.

KUALA LUMPUR: Malaysia is the first country in Asia to start clinical study of ovarian cancer diagnostic blood test in early 2019, said chief executive officer (CEO) of Clinical Research Malaysia (CRM), Dr. Akhmal Yusof.

This is following an institutional investment of RM39 million by InterVenn BioSciences, a biotech company based in USA to develop the cancer early detection blood test in collaboration with CRM and Technology Park Malaysia (TPM).

TPM acting president/CEO, Sharbani Harun said that the collaboration marked an important milestone for Malaysia to become a central hub for the Asia-Pacific region, towards the advancement of research and development in the field of biomedical and life sciences.

Meanwhile, Dr. Akhmal added InterVenn’s decision to conduct clinical study here is a testament to the country’s capabilities in terms of infrastructure, good clinical practice, certified investigators and a large patient pool.

Once clinical validation and regulatory processes are completed, the ovarian cancer blood test will be offered as a laboratory diagnostic test.

The investment is led by San Francisco-based biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC and Prado SV.

InterVenn has also established subsidiaries in Kuala Lumpur and Manila to foster biotechnology, drive AI adoption and support Industrial Revolution 4.0 in Southeast Asia.

– Bernama

We have moved to new office!

Clinical Research Malaysia has now moved to our new office to provide better service for clinical research. We now operate from:

D-26-06, Menara Suezcap 1,
KL Gateway, No. 2 Jalan Kerinchi,
Gerbang Kerinchi Lestari,
59200 Kuala Lumpur.

We could be contacted through:

Phone number: +603 7931 5566
Facsimile number: +603 7931 9940

Our individual team member emails remain unchanged and if you need further clarification you could write to contact@clinicalresearch.my

We appreciate your continuous support and look forward to continuing growing clinical research in Malaysia together from the new office.

 

Sincerely,
The Management of CRM

Silicon Valley-Based InterVenn BioSciences Raises RM 39 Million, Establishes Subsidiary in Malaysia to Develop Ovarian Cancer Early Detection Blood Test in Collaboration with TPM and CRM

KUALA LUMPUR, Dec 14 (Bernama) — InterVenn BioSciences, a biotech company innovating cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, announced this week an institutional investment of US$9.4 million led by San Francisco-based biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV.

Headquartered in Silicon Valley, USA, InterVenn has established subsidiaries in Kuala Lumpur and Manila to foster biotechnology, drive AI adoption, and support Industrial Revolution 4.0 in Southeast Asia. The company is conducting analytical and clinical validation of its ovarian cancer diagnostic blood test. A global, multi-site clinical study to validate this test will commence in early 2019. Clinical Research Malaysia (CRM), an agency under the Malaysia Ministry of Health, plays a vital role in supporting InterVenn’s clinical operations in Malaysia and facilitated fifteen clinical sites across nine states in Malaysia for this clinical study.

InterVenn’s established strategic partnership with Technology Park Malaysia (TPM) in 2017, an agency under the Malaysia Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), to build an internationally-certified clinical laboratory, attract and upskill a critical scientific talent pool in Malaysia.

Once clinical validation and regulatory processes are completed, the ovarian cancer blood test will be offered as a laboratory diagnostic test. “Today, early diagnosis of ovarian cancer is extremely poor, despite its role in significantly improving survival rates,” said Aldo Carrascoso, CEO of InterVenn BioSciences. “We’ve established a talented team of experts in AI, computational biology, mass spectrometry, glycoproteomics, and product development who are dedicated to equipping physicians with a reliable tool to change the narrative around ovarian cancer. ”

“InterVenn’s decision to conduct their clinical study in Malaysia is testament to the country’s capabilities in terms of infrastructure, good clinical practice, certified investigators and a large patient pool,” said Dr. Akhmal Yusof, CEO of Clinical Research Malaysia. “InterVenn can capitalize on the services that CRM provides to ensure smooth conduct and delivery of their trials. I’m proud that Malaysia will be the first country in Asia that will start this clinical study next year and hopefully Malaysia can contribute to InterVenn’s exponential growth further in the near future.”

Meanwhile, TPM Acting President/CEO, Encik Sharbani Harun said that the collaborative efforts between InterVenn and TPM marked an important milestone for Malaysia to become a central hub for the Asia-Pacific region, towards the advancement of research and development in the field of biomedical and life sciences. “We are certainly proud to be given the opportunity to work closely with InterVenn whereby they will be the utilizing our world-class laboratory equipment and facilities to further their cancer diagnostic innovation,” added Sharbani.

InterVenn aims to lead the next wave of precision medicine by enabling innovation in diagnostics and therapeutics through global collaborations to improve human health. The partnership with TPM and CRM serve as a launchpad for this mission.

–BERNAMA